Skip to main content
TGTX
NASDAQ Life Sciences

TG Therapeutics Q3 2026: Revenue $259.9M, Net Income $55.5M, $556.7M Cash

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$63.55
Mkt Cap
$9.702B
52W Low
$26.76
52W High
$63.6
52W Position info
137% above low
Off High info
at 52W high
Rel. Volume info
2.6× avg
Market data snapshot near publication time

TGTX has more than doubled off its 52-week low of $26.76 on elevated volume (2.6× avg).

Summary

TG Therapeutics' Q3 2026 10-Q shows revenue of $259.9M, net income of $55.5M ($0.35 diluted EPS) and $556.7M in cash and investments, with $100.0M left on the buyback authorization.


Key Events · Earnings and Guidance · TGTX

  • Q3 Revenue Jumps 61%

    Total revenue was $259.9M versus $161.7M a year ago, with BRIUMVI U.S. net sales of $232.6M and $7.4M to Neuraxpharm.

  • Operating Income $85.9M

    Operating income reached $85.9M and net income $55.5M, or $0.35 diluted EPS; nine-month revenue was $705.2M.

  • Cash and Investments $556.7M

    Cash, cash equivalents and investment securities totaled $556.7M at September 30, 2026, with nine-month operating cash flow of $66.6M.

  • Buyback $100.0M Remaining

    The company repurchased 2,023,452 shares at an average of $49.43 in Q3, leaving $100.0M available under the $300M 2025 program.


Analysis · TGTX · Life Sciences

The 10-Q fills in the numbers behind this morning's 8-K headline. Q3 revenue of $259.9M (up from $161.7M a year ago) produced operating income of $85.9M and net income of $55.5M, or $0.35 diluted EPS. The balance sheet is the real story: $556.7M in cash and investment securities after a $750M Blue Owl term loan refinancing in March and roughly $200M of buybacks under the 2025 program, with $100.0M of repurchase capacity left. Nine-month operating cash flow turned positive at $66.6M versus a $44.4M outflow a year ago. The prior-year net income of $390.9M was inflated by a $371.7M deferred-tax valuation allowance release, so the year-over-year net income drop is an accounting comparison, not an operating deterioration.

How filings like this one have moved

In the 30 days to Nov 9, 2026, 47.1% of the 1533 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TGTX was trading at $63.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.7B. The 52-week trading range was $26.76 to $63.60. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TGTX - Latest Insights

TGTX
Nov 09, 2026, 7:04 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $63.00
Real-time Price: $63.55 info
Change: +$0.550 (+0.87%) info
Market Cap: $9.702B info
TGTX
Nov 09, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $58.11
Real-time Price: $63.55 info
Change: +$5.44 (+9%) info
Market Cap: $9.702B info
TGTX
Oct 23, 2026, 11:03 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $52.44
Real-time Price: $63.55 info
Change: +$11.11 (+21%) info
Market Cap: $9.702B info
TGTX
Aug 05, 2026, 5:01 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $50.48
Real-time Price: $63.55 info
Change: +$13.07 (+26%) info
Market Cap: $9.702B info
TGTX
Aug 03, 2026, 9:22 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $51.30
Real-time Price: $63.55 info
Change: +$12.25 (+24%) info
Market Cap: $9.702B info